A number of therapies from a range of drug classes are available to treat the symptoms of narcolepsy (e.g., excessive daytime sleepiness, cataplexy). Our Treatment Algorithms research leverages national patient-level claims data to explore the use of key therapies for narcolepsy, such as modafinil, armodafinil, and Xyrem, in both newly diagnosed and recently treated patients. These data provide important information regarding the patient journey in narcolepsy, including treatment duration, switch patterns, and persistence and compliance by drug.
Treatment Algorithms: Claims Data Analysis: Provides detailed analysis of brand use across different lines of therapy using real-world patient-level claims data so that clients can accurately assess their source of business and quantify areas of opportunity to increase their brand share.
Markets covered: United States
Real-world data: Longitudinal patient-level claims data analysis
Key companies: Teva, Jazz Pharmaceuticals, Shire, Pfizer, Eli Lilly
Key drugs: Xyrem, Vyvanse, armodafinil (Nuvigil, generics), modafinil (Provigil, generics), atomoxetine (Strattera, generics)
Key analysis provided: